AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk

Group 1 - AbbVie Inc. has entered the obesity treatment market by in-licensing GUB014295 (GUBamy) from Gubra, a Denmark-based company [2] - GUB014295 is a long-acting amylin analog aimed at treating obesity, indicating AbbVie's strategic expansion into a new therapeutic area [2]